Kräuterblut
Phase 1Small molecule
Kräuterblut is one of 24 small molecule programs targeting Total Knee Arthroplasty. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Cymbalta
Alnylam PharmaceuticalsPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xarelto
WWim Janssens
Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Zanaflex
LLegacy Health System
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Botox
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kräuterblut. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details